Journal of Crohns & Colitis-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2018-12-17 zhihenghuang

审稿速度:3.0 | 投稿命中率:25.0
经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿
投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿
投稿时间：11-Dec-2018，等待中

251 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2017-09-03 lj998877

你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表::
审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表:
2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.

明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.

397 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2017-08-19 明真

审稿速度:2.0
经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。

357 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2016-08-07 zhihenghuang

审稿速度:2.0 | 投稿命中率:25.0
经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了

356 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2016-05-25 variant

这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了

307 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2013-12-20 jacky19820312

看好这个杂志

268 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2013-05-01 qiuxinyun2819

Lead times:

Number of instant rejections: 9%
Average time to first decision (= reviewers time): 22 days
Average time from acceptance to online: 12.4 days

Average time to acceptance, see following table Editor decision Summary.

The following breakdown displays in percentages of manuscripts published per world region:

Asia: 6%
Australia: 2%
Eastern Europe: 4%
Central America: 0.7%
Middle East: 7%
South America: 0.7%
North America: 20%
Western Europe: 60%

401 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2013-05-01 qiuxinyun2819

审稿速度:1.0 | 投稿命中率:50.0
经验分享：Journals Statistics:

Acceptance rate: 57% for papers submitted in 2013
Frequency: 12 issues
Impact Factor: 2.566
Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science
Launch date: 2007
ISSN: 1873-9946

322 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2013-04-09 匿名用户

杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！

344 0

[GetPortalCommentsPageByObjectIdResponse(id=564530, encodeId=6244564530bb, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：投稿时间：08-Mar-2016 返回15-Apr-2016，结果：拒稿 投稿时间：17-Jun-2016 返回：07-Sep-2016，结果：拒稿 投稿时间：11-Dec-2018，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Mon Dec 17 07:18:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546232, encodeId=725a54623288, content=你好.我最近准备投这个杂志.请问需要注意些什么.谢谢!明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右.明真 2017-08-19 04:02:00 发表: 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., beContent=明真 2017-08-19 发表:: 审稿时间:约2个月 2017年6月15号投稿,2017年7月13号审稿意见返回.小修,一星期后返回.2017年8月10号接受.总体来说审稿速度挺快.比较幸运.该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高.长期来看.IF在6左右., objectType=tool_impact_factor, channel=null, level=null, likeNumber=397, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a21630031, createdName=lj998877, createdTime=Sun Sep 03 00:00:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=545668, encodeId=328c54566824, content=审稿速度:2.0 经验分享：2017年6月15号投稿；2017年7月13号审稿意见返回，小修；一星期后返回，2017年8月10号接受。总体来说审稿速度挺快，比较幸运。该杂志虽说影响力不及Journal of inflammatory bowel diseases, 但是拒稿率超高。长期来看，IF在6左右。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=357, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJVbYz6mg6hibGa6AyicIUiaH4ye5x78GCUw44vzMg31uuH41ZMb7Ke6uq08H9iaWQhjEZibq7tNIiaMVpw/132, createdBy=a2361943123, createdName=明真, createdTime=Sat Aug 19 04:02:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=525626, encodeId=7ce952562693, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：2016.6.17投稿到现在2016.8.7 还在审稿中，也挺慢的。不过我上一篇病例报道，1个月时间就有消息了，给据掉了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=356, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb9b27436, createdName=zhihenghuang, createdTime=Sun Aug 07 16:36:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=522826, encodeId=7eca5228264b, content=这个杂志的JCR分区是胃肠肝病学分类下的1区期刊，这里怎么显示错了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ed41640007, createdName=variant, createdTime=Wed May 25 10:13:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=500284, encodeId=376950028464, content=看好这个杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f8ea91996, createdName=jacky19820312, createdTime=Fri Dec 20 14:29:00 CST 2013, time=2013-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495411, encodeId=638e4954115e, content=Lead times: Number of instant rejections: 9% Average time to first decision (= reviewers time): 22 days Average time from acceptance to online: 12.4 days Average time to acceptance, see following table Editor decision Summary. The following breakdown displays in percentages of manuscripts published per world region: Asia: 6% Australia: 2% Eastern Europe: 4% Central America: 0.7% Middle East: 7% South America: 0.7% North America: 20% Western Europe: 60% , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=401, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=495410, encodeId=1abf4954109e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：Journals Statistics: Acceptance rate: 57% for papers submitted in 2013 Frequency: 12 issues Impact Factor: 2.566 Indexed by: Current Contents, EBSCOhost, EMBASE, Excerpta Medica, MEDLINE, Reactions Weekly, Science Citation Index Expanded, Scopus and Web of Science Launch date: 2007 ISSN: 1873-9946 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=125b80202, createdName=qiuxinyun2819, createdTime=Wed May 01 15:52:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=494941, encodeId=3474494941b2, content=杂志审稿很快！一般一审一个月内给建议！我投了两次稿，第一次一个月内拒稿，第二次一个月内小修，修回后20天内接收！很负责任的杂志！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 09 10:13:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481118, encodeId=63054811181a, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]

2011-06-29 medwu

看涨哦，如果明天再升一升，有望突破3分

307 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务